TCMD · Tactile Systems Technology Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $75.27M | - | $85.75M | $78.91M | $61.27M | - | $73.09M | $73.22M | $61.09M | - |
| Cost of Revenue | $17.65M | - | $20.75M | $20.11M | $15.92M | - | $18.31M | $19.11M | $17.66M | - |
| Gross Profit | $57.61M | - | $65.00M | $58.79M | $45.35M | - | $54.79M | $54.10M | $43.43M | - |
| R&D | $2.78M | - | $2.19M | $2.02M | $1.74M | - | $2.42M | $2.23M | $2.14M | - |
| SG&A | $23.04M | - | $21.44M | $22.03M | $20.00M | - | $18.12M | $16.78M | $16.26M | - |
| Total Operating Expenses | $59.15M | - | $54.04M | $54.71M | $49.89M | - | $48.01M | $48.25M | $46.39M | - |
| D&A | $1.64M | - | - | - | $1.73M | - | - | - | $1.63M | - |
| Operating Income | ($1.53M) | - | $10.96M | $4.08M | ($4.54M) | - | $6.78M | $5.85M | ($2.96M) | - |
| Interest Expense | $28.0K | - | $517.0K | $529.0K | $567.0K | - | - | - | - | - |
| Income Tax | $867.0K | - | $3.23M | $1.31M | ($1.10M) | - | $2.08M | $1.78M | ($600.0K) | - |
| Net Income | ($1.76M) | - | $8.21M | $3.22M | ($2.97M) | - | $5.16M | $4.30M | ($2.21M) | - |
| EPS - Basic | ($0.08) | - | $0.37 | $0.14 | ($0.13) | - | $0.21 | $0.18 | ($0.09) | - |
| EPS - Diluted | ($0.08) | - | $0.36 | $0.14 | ($0.13) | - | $0.21 | $0.18 | ($0.09) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $74.99M | $83.45M | $65.97M | $81.53M | $83.62M | $94.37M | $82.15M | $73.62M | $60.71M | $61.03M |
| Accounts Receivable | $38.22M | $43.88M | $37.26M | $33.09M | $35.69M | $44.94M | $39.97M | $41.94M | $40.49M | $43.17M |
| Inventory | $16.58M | $14.03M | $16.08M | $17.11M | $18.87M | $18.67M | $21.18M | $18.85M | $20.84M | $22.53M |
| Accounts Payable | $7.12M | $4.97M | $7.99M | $8.03M | $7.22M | $5.65M | $7.29M | $5.09M | $5.49M | $6.66M |
| Current Assets | $152.84M | $165.17M | $141.40M | $152.99M | $160.12M | $177.56M | $162.37M | $151.86M | $141.27M | $145.29M |
| Total Assets | $272.12M | $273.94M | $259.18M | $273.05M | $280.24M | $297.92M | $287.72M | $278.78M | $272.04M | $281.44M |
| Current Liabilities | $36.01M | $40.96M | $39.19M | $40.40M | $35.40M | $40.70M | $37.15M | $34.21M | $33.13M | $41.06M |
| Long-term Debt | $0 | $0 | $0 | - | - | - | $27.00M | $27.80M | $28.50M | $16.80M |
| Total Liabilities | $54.25M | $55.04M | $54.23M | $78.12M | $74.61M | $81.33M | $79.82M | $78.11M | $78.57M | $87.80M |
| Stockholders' Equity | $217.87M | $218.90M | $204.95M | $194.93M | $205.63M | $216.60M | $207.90M | $200.68M | $193.47M | $193.64M |
| Retained Earnings | $53.18M | $54.94M | $44.31M | $36.10M | $32.88M | $35.85M | $26.14M | $20.98M | $16.68M | $18.89M |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($339.0K) | - | - | - | $417.0K | - | - | - | $924.0K | - |
| Investing Cash Flow | ($7.06M) | - | - | - | ($407.0K) | - | - | - | ($502.0K) | - |
| Financing Cash Flow | ($1.05M) | - | - | - | ($10.76M) | - | - | - | ($749.0K) | - |
| CapEx | $821.0K | - | - | - | $379.0K | - | - | - | $482.0K | - |
| Free Cash Flow | ($1.16M) | - | - | - | $38.0K | - | - | - | $442.0K | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 76.5% | - | 75.8% | 74.5% | 74.0% | - | 75.0% | 73.9% | 71.1% | - |
| Operating margin | -2.0% | - | 12.8% | 5.2% | -7.4% | - | 9.3% | 8.0% | -4.9% | - |
| EBITDA margin | 0.1% | - | - | - | -4.6% | - | - | - | -2.2% | - |
| Net margin | -2.3% | - | 9.6% | 4.1% | -4.9% | - | 7.1% | 5.9% | -3.6% | - |
| Free cash flow margin | -1.5% | - | - | - | 0.1% | - | - | - | 0.7% | - |
| FCF / Net income | 0.66 | - | - | - | -0.01 | - | - | - | -0.20 | - |
| R&D / Revenue | 3.7% | - | 2.6% | 2.6% | 2.8% | - | 3.3% | 3.1% | 3.5% | - |
| SG&A / Revenue | 30.6% | - | 25.0% | 27.9% | 32.6% | - | 24.8% | 22.9% | 26.6% | - |
| Effective tax rate | - | - | 28.2% | 28.9% | - | - | 28.7% | 29.2% | - | - |
| Return on assets | -0.6% | - | 3.2% | 1.2% | -1.1% | - | 1.8% | 1.5% | -0.8% | - |
| Return on equity | -0.8% | - | 4.0% | 1.7% | -1.4% | - | 2.5% | 2.1% | -1.1% | - |
| Return on invested capital | -0.6% | - | 3.8% | - | - | - | 2.1% | 1.8% | -1.1% | - |
| Liquidity | ||||||||||
| Current ratio | 4.24 | 4.03 | 3.61 | 3.79 | 4.52 | 4.36 | 4.37 | 4.44 | 4.26 | 3.54 |
| Quick ratio | 3.78 | 3.69 | 3.20 | 3.36 | 3.99 | 3.90 | 3.80 | 3.89 | 3.63 | 2.99 |
| Cash ratio | 2.08 | 2.04 | 1.68 | 2.02 | 2.36 | 2.32 | 2.21 | 2.15 | 1.83 | 1.49 |
| Leverage | ||||||||||
| Debt / Equity | 0.00 | 0.00 | 0.00 | - | - | - | 0.13 | 0.14 | 0.15 | 0.09 |
| Debt / Assets | 0.00 | 0.00 | 0.00 | - | - | - | 0.09 | 0.10 | 0.10 | 0.06 |
| Debt / EBITDA | 0.00 | - | - | - | - | - | - | - | - | - |
| Interest coverage | -54.8x | - | 21.2x | 7.7x | -8.0x | - | - | - | - | - |
| Equity multiplier | 1.25 | 1.25 | 1.26 | 1.40 | 1.36 | 1.38 | 1.38 | 1.39 | 1.41 | 1.45 |
| Liabilities / Assets | 0.20 | 0.20 | 0.21 | 0.29 | 0.27 | 0.27 | 0.28 | 0.28 | 0.29 | 0.31 |
| Efficiency | ||||||||||
| Asset turnover | 0.28 | - | 0.33 | 0.29 | 0.22 | - | 0.25 | 0.26 | 0.22 | - |
| Inventory turnover | 1.06 | - | 1.29 | 1.18 | 0.84 | - | 0.86 | 1.01 | 0.85 | - |
| Days sales outstanding | 185d | - | 159d | 153d | 213d | - | 200d | 209d | 242d | - |
| Days inventory outstanding | 343d | - | 283d | 311d | 433d | - | 422d | 360d | 431d | - |
| Days payable outstanding | 147d | - | 141d | 146d | 166d | - | 145d | 97d | 113d | - |
| Cash conversion cycle | 381d | - | 301d | 318d | 480d | - | 476d | 472d | 559d | - |
| Valuation | ||||||||||
| P / E | - | - | 38.4x | 72.4x | - | - | 69.6x | 66.3x | - | - |
| P / B | 2.7x | - | 1.5x | 1.2x | 1.5x | - | 1.7x | 1.4x | 2.0x | - |
| P / S | 7.8x | - | 3.6x | 3.0x | 5.1x | - | 4.8x | 3.9x | 6.3x | - |
| EV / EBITDA | 4900.3x | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 22.8% | - | 17.3% | 7.8% | 0.3% | - | 5.0% | 7.1% | 3.8% | - |
| Revenue CAGR (3y) | 8.5% | - | 9.5% | 9.8% | 8.5% | - | 11.7% | 12.8% | 12.6% | - |
| Revenue CAGR (5y) | 12.0% | - | 11.8% | 17.6% | 7.0% | - | 8.1% | 10.1% | 10.2% | - |
| Gross profit growth (YoY) | 27.1% | - | 18.6% | 8.7% | 4.4% | - | 11.0% | 12.0% | 4.7% | - |
| Operating income growth (YoY) | 66.2% | - | 61.7% | -30.2% | -53.2% | - | -15.1% | 184.2% | 22.1% | - |
| Net income growth (YoY) | 40.7% | - | 59.2% | -25.2% | -34.6% | - | -76.9% | - | -17.1% | - |
| EPS growth (YoY) | 38.5% | - | 71.4% | -22.2% | -44.4% | - | -77.7% | - | 0.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | 37.0% | - | - |
| EPS CAGR (5y) | - | - | 24.6% | - | - | - | 11.8% | 5.2% | - | - |
| FCF growth (YoY) | - | - | - | - | -91.4% | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | -41.4% | - | - | - | -4.0% | - |
| Book value growth (YoY) | 5.9% | 1.1% | -1.4% | -2.9% | 6.3% | 11.9% | 13.7% | 26.4% | 23.9% | 59.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$659.04M totalProduct$292.59M · 44.4%
Lymphedema Products$278.38M · 42.2%
Airway Clearance Products$51.14M · 7.8%
Rental Product Service$36.93M · 5.6%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing TACTILE SYSTEMS TECHNOLOGY INC against the 5 most active filers in the same SIC group.